Evaluation of assays for drug efficacy in a three-dimensional model of the lung

Background The focus of the outlined work is the establishment of a three-dimensional lung model for various drug-screening applications. Methods The non-small cell lung cancer (NSCLC) cell line Colo699 was cultivated as monolayer (2D) on plates for 5 days or as microtissues (3D) using a hanging-dro...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of cancer research and clinical oncology 2016-09, Vol.142 (9), p.1955-1966
Hauptverfasser: Huber, Julia M., Amann, Arno, Koeck, Stefan, Lorenz, Edith, Kelm, Jens M., Obexer, Petra, Zwierzina, Heinz, Gamerith, Gabriele
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1966
container_issue 9
container_start_page 1955
container_title Journal of cancer research and clinical oncology
container_volume 142
creator Huber, Julia M.
Amann, Arno
Koeck, Stefan
Lorenz, Edith
Kelm, Jens M.
Obexer, Petra
Zwierzina, Heinz
Gamerith, Gabriele
description Background The focus of the outlined work is the establishment of a three-dimensional lung model for various drug-screening applications. Methods The non-small cell lung cancer (NSCLC) cell line Colo699 was cultivated as monolayer (2D) on plates for 5 days or as microtissues (3D) using a hanging-drop system for 5 and 10 days. Cells and microtissues were treated with afatinib (10–80 µM), cisplatin (100–800 µM) or vinorelbine (25–200 µM) for 24 or 48 hours (h). Cell proliferation and viability were analysed by intra-cellular adenosine triphosphate (ATP) and lactate dehydrogenase release (LDH) assays, annexin V/propidium iodide (PI) staining, and cell cycle determination. Microtissue morphology and size, as well as cell death were evaluated via phase contrast microscopy. Results Our results demonstrate the valid determination of viability and cell death using established assays in the 3D system for drug testing. The comparison of ATP, LDH and cytometry data showed moderate (0.40) to very strong (0.99) correlations. Thereby, we observed partially significant differences in drug efficacy between microtissues and 2D cultures dependent from the applied treatment and read-out method. Altogether, microtissues developed resistance to cisplatin and vinorelbine; but remained more vulnerable to afatinib. These findings were confirmed with microscopy. Conclusion In summary, we established an NSCLC 3D test system with multiple assays compatible for drug-testing applications of substances with different mechanisms of action. In addition, our data support the usage of microtissues as more accurate tools for drug-efficacy testing with the possibility of long-term cultivation and treatment.
doi_str_mv 10.1007/s00432-016-2198-0
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4978763</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4144581461</sourcerecordid><originalsourceid>FETCH-LOGICAL-c503t-e7ca3711c086d6eb86e3c97921ed54b525ba3df4393f5ae26e6b891ee4deb3c23</originalsourceid><addsrcrecordid>eNqNkU9rFTEUxYNY7LP6AdxIwI2bsbn5O9kIUloVCt3oOmQyd96bMjOpyUzhfXszTFuqILhJSO7vnJubQ8g7YJ-AMXOeGZOCVwx0xcHWFXtBdrDegBDqJdkxMFApDvqUvM75lpWzMvwVOeVGcgm13ZGby3s_LH7u40RjR33O_phpFxNt07Kn2HV98OFI-4l6Oh8SYtX2I065CPxAx9jisArnA9JhmfZvyEnnh4xvH_Yz8vPq8sfFt-r65uv3iy_XVVBMzBWa4IUBCKzWrcam1iiCNZYDtko2iqvGi7aTwopOeeQadVNbQJQtNiJwcUY-b753SzNiG3Cakx_cXepHn44u-t79WZn6g9vHeyetqY0WxeDjg0GKvxbMsxv7HHAY_IRxyQ5qUIYZbeX_oGUMBZIV9MNf6G1cUvmpjdK2rFAo2KiQYs4Ju6d3A3Nrsm5L1pVk3ZqsW53fPx_4SfEYZQH4BuRSmvaYnrX-p-tvf0quPw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1810691811</pqid></control><display><type>article</type><title>Evaluation of assays for drug efficacy in a three-dimensional model of the lung</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Huber, Julia M. ; Amann, Arno ; Koeck, Stefan ; Lorenz, Edith ; Kelm, Jens M. ; Obexer, Petra ; Zwierzina, Heinz ; Gamerith, Gabriele</creator><creatorcontrib>Huber, Julia M. ; Amann, Arno ; Koeck, Stefan ; Lorenz, Edith ; Kelm, Jens M. ; Obexer, Petra ; Zwierzina, Heinz ; Gamerith, Gabriele</creatorcontrib><description>Background The focus of the outlined work is the establishment of a three-dimensional lung model for various drug-screening applications. Methods The non-small cell lung cancer (NSCLC) cell line Colo699 was cultivated as monolayer (2D) on plates for 5 days or as microtissues (3D) using a hanging-drop system for 5 and 10 days. Cells and microtissues were treated with afatinib (10–80 µM), cisplatin (100–800 µM) or vinorelbine (25–200 µM) for 24 or 48 hours (h). Cell proliferation and viability were analysed by intra-cellular adenosine triphosphate (ATP) and lactate dehydrogenase release (LDH) assays, annexin V/propidium iodide (PI) staining, and cell cycle determination. Microtissue morphology and size, as well as cell death were evaluated via phase contrast microscopy. Results Our results demonstrate the valid determination of viability and cell death using established assays in the 3D system for drug testing. The comparison of ATP, LDH and cytometry data showed moderate (0.40) to very strong (0.99) correlations. Thereby, we observed partially significant differences in drug efficacy between microtissues and 2D cultures dependent from the applied treatment and read-out method. Altogether, microtissues developed resistance to cisplatin and vinorelbine; but remained more vulnerable to afatinib. These findings were confirmed with microscopy. Conclusion In summary, we established an NSCLC 3D test system with multiple assays compatible for drug-testing applications of substances with different mechanisms of action. In addition, our data support the usage of microtissues as more accurate tools for drug-efficacy testing with the possibility of long-term cultivation and treatment.</description><identifier>ISSN: 0171-5216</identifier><identifier>EISSN: 1432-1335</identifier><identifier>DOI: 10.1007/s00432-016-2198-0</identifier><identifier>PMID: 27424189</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Cancer ; Cancer Research ; Cell Cycle - drug effects ; Cell Proliferation - drug effects ; Cisplatin - pharmacology ; Drug Screening Assays, Antitumor - methods ; Drug therapy ; Hematology ; Humans ; Internal Medicine ; Lung - cytology ; Lung - pathology ; Lung Neoplasms - pathology ; Medical screening ; Medicine ; Medicine &amp; Public Health ; Oncology ; Original Article – Cancer Research ; Original – Cancer Research ; Quinazolines - pharmacology ; Spheroids, Cellular - cytology ; Three dimensional imaging ; Tissue Culture Techniques - methods ; Tumor Cells, Cultured ; Vinblastine - analogs &amp; derivatives ; Vinblastine - pharmacology</subject><ispartof>Journal of cancer research and clinical oncology, 2016-09, Vol.142 (9), p.1955-1966</ispartof><rights>The Author(s) 2016</rights><rights>Springer-Verlag Berlin Heidelberg 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c503t-e7ca3711c086d6eb86e3c97921ed54b525ba3df4393f5ae26e6b891ee4deb3c23</citedby><cites>FETCH-LOGICAL-c503t-e7ca3711c086d6eb86e3c97921ed54b525ba3df4393f5ae26e6b891ee4deb3c23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00432-016-2198-0$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00432-016-2198-0$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,778,782,883,27911,27912,41475,42544,51306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27424189$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Huber, Julia M.</creatorcontrib><creatorcontrib>Amann, Arno</creatorcontrib><creatorcontrib>Koeck, Stefan</creatorcontrib><creatorcontrib>Lorenz, Edith</creatorcontrib><creatorcontrib>Kelm, Jens M.</creatorcontrib><creatorcontrib>Obexer, Petra</creatorcontrib><creatorcontrib>Zwierzina, Heinz</creatorcontrib><creatorcontrib>Gamerith, Gabriele</creatorcontrib><title>Evaluation of assays for drug efficacy in a three-dimensional model of the lung</title><title>Journal of cancer research and clinical oncology</title><addtitle>J Cancer Res Clin Oncol</addtitle><addtitle>J Cancer Res Clin Oncol</addtitle><description>Background The focus of the outlined work is the establishment of a three-dimensional lung model for various drug-screening applications. Methods The non-small cell lung cancer (NSCLC) cell line Colo699 was cultivated as monolayer (2D) on plates for 5 days or as microtissues (3D) using a hanging-drop system for 5 and 10 days. Cells and microtissues were treated with afatinib (10–80 µM), cisplatin (100–800 µM) or vinorelbine (25–200 µM) for 24 or 48 hours (h). Cell proliferation and viability were analysed by intra-cellular adenosine triphosphate (ATP) and lactate dehydrogenase release (LDH) assays, annexin V/propidium iodide (PI) staining, and cell cycle determination. Microtissue morphology and size, as well as cell death were evaluated via phase contrast microscopy. Results Our results demonstrate the valid determination of viability and cell death using established assays in the 3D system for drug testing. The comparison of ATP, LDH and cytometry data showed moderate (0.40) to very strong (0.99) correlations. Thereby, we observed partially significant differences in drug efficacy between microtissues and 2D cultures dependent from the applied treatment and read-out method. Altogether, microtissues developed resistance to cisplatin and vinorelbine; but remained more vulnerable to afatinib. These findings were confirmed with microscopy. Conclusion In summary, we established an NSCLC 3D test system with multiple assays compatible for drug-testing applications of substances with different mechanisms of action. In addition, our data support the usage of microtissues as more accurate tools for drug-efficacy testing with the possibility of long-term cultivation and treatment.</description><subject>Cancer</subject><subject>Cancer Research</subject><subject>Cell Cycle - drug effects</subject><subject>Cell Proliferation - drug effects</subject><subject>Cisplatin - pharmacology</subject><subject>Drug Screening Assays, Antitumor - methods</subject><subject>Drug therapy</subject><subject>Hematology</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Lung - cytology</subject><subject>Lung - pathology</subject><subject>Lung Neoplasms - pathology</subject><subject>Medical screening</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Oncology</subject><subject>Original Article – Cancer Research</subject><subject>Original – Cancer Research</subject><subject>Quinazolines - pharmacology</subject><subject>Spheroids, Cellular - cytology</subject><subject>Three dimensional imaging</subject><subject>Tissue Culture Techniques - methods</subject><subject>Tumor Cells, Cultured</subject><subject>Vinblastine - analogs &amp; derivatives</subject><subject>Vinblastine - pharmacology</subject><issn>0171-5216</issn><issn>1432-1335</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqNkU9rFTEUxYNY7LP6AdxIwI2bsbn5O9kIUloVCt3oOmQyd96bMjOpyUzhfXszTFuqILhJSO7vnJubQ8g7YJ-AMXOeGZOCVwx0xcHWFXtBdrDegBDqJdkxMFApDvqUvM75lpWzMvwVOeVGcgm13ZGby3s_LH7u40RjR33O_phpFxNt07Kn2HV98OFI-4l6Oh8SYtX2I065CPxAx9jisArnA9JhmfZvyEnnh4xvH_Yz8vPq8sfFt-r65uv3iy_XVVBMzBWa4IUBCKzWrcam1iiCNZYDtko2iqvGi7aTwopOeeQadVNbQJQtNiJwcUY-b753SzNiG3Cakx_cXepHn44u-t79WZn6g9vHeyetqY0WxeDjg0GKvxbMsxv7HHAY_IRxyQ5qUIYZbeX_oGUMBZIV9MNf6G1cUvmpjdK2rFAo2KiQYs4Ju6d3A3Nrsm5L1pVk3ZqsW53fPx_4SfEYZQH4BuRSmvaYnrX-p-tvf0quPw</recordid><startdate>20160901</startdate><enddate>20160901</enddate><creator>Huber, Julia M.</creator><creator>Amann, Arno</creator><creator>Koeck, Stefan</creator><creator>Lorenz, Edith</creator><creator>Kelm, Jens M.</creator><creator>Obexer, Petra</creator><creator>Zwierzina, Heinz</creator><creator>Gamerith, Gabriele</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20160901</creationdate><title>Evaluation of assays for drug efficacy in a three-dimensional model of the lung</title><author>Huber, Julia M. ; Amann, Arno ; Koeck, Stefan ; Lorenz, Edith ; Kelm, Jens M. ; Obexer, Petra ; Zwierzina, Heinz ; Gamerith, Gabriele</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c503t-e7ca3711c086d6eb86e3c97921ed54b525ba3df4393f5ae26e6b891ee4deb3c23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Cancer</topic><topic>Cancer Research</topic><topic>Cell Cycle - drug effects</topic><topic>Cell Proliferation - drug effects</topic><topic>Cisplatin - pharmacology</topic><topic>Drug Screening Assays, Antitumor - methods</topic><topic>Drug therapy</topic><topic>Hematology</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Lung - cytology</topic><topic>Lung - pathology</topic><topic>Lung Neoplasms - pathology</topic><topic>Medical screening</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Oncology</topic><topic>Original Article – Cancer Research</topic><topic>Original – Cancer Research</topic><topic>Quinazolines - pharmacology</topic><topic>Spheroids, Cellular - cytology</topic><topic>Three dimensional imaging</topic><topic>Tissue Culture Techniques - methods</topic><topic>Tumor Cells, Cultured</topic><topic>Vinblastine - analogs &amp; derivatives</topic><topic>Vinblastine - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Huber, Julia M.</creatorcontrib><creatorcontrib>Amann, Arno</creatorcontrib><creatorcontrib>Koeck, Stefan</creatorcontrib><creatorcontrib>Lorenz, Edith</creatorcontrib><creatorcontrib>Kelm, Jens M.</creatorcontrib><creatorcontrib>Obexer, Petra</creatorcontrib><creatorcontrib>Zwierzina, Heinz</creatorcontrib><creatorcontrib>Gamerith, Gabriele</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of cancer research and clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Huber, Julia M.</au><au>Amann, Arno</au><au>Koeck, Stefan</au><au>Lorenz, Edith</au><au>Kelm, Jens M.</au><au>Obexer, Petra</au><au>Zwierzina, Heinz</au><au>Gamerith, Gabriele</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of assays for drug efficacy in a three-dimensional model of the lung</atitle><jtitle>Journal of cancer research and clinical oncology</jtitle><stitle>J Cancer Res Clin Oncol</stitle><addtitle>J Cancer Res Clin Oncol</addtitle><date>2016-09-01</date><risdate>2016</risdate><volume>142</volume><issue>9</issue><spage>1955</spage><epage>1966</epage><pages>1955-1966</pages><issn>0171-5216</issn><eissn>1432-1335</eissn><abstract>Background The focus of the outlined work is the establishment of a three-dimensional lung model for various drug-screening applications. Methods The non-small cell lung cancer (NSCLC) cell line Colo699 was cultivated as monolayer (2D) on plates for 5 days or as microtissues (3D) using a hanging-drop system for 5 and 10 days. Cells and microtissues were treated with afatinib (10–80 µM), cisplatin (100–800 µM) or vinorelbine (25–200 µM) for 24 or 48 hours (h). Cell proliferation and viability were analysed by intra-cellular adenosine triphosphate (ATP) and lactate dehydrogenase release (LDH) assays, annexin V/propidium iodide (PI) staining, and cell cycle determination. Microtissue morphology and size, as well as cell death were evaluated via phase contrast microscopy. Results Our results demonstrate the valid determination of viability and cell death using established assays in the 3D system for drug testing. The comparison of ATP, LDH and cytometry data showed moderate (0.40) to very strong (0.99) correlations. Thereby, we observed partially significant differences in drug efficacy between microtissues and 2D cultures dependent from the applied treatment and read-out method. Altogether, microtissues developed resistance to cisplatin and vinorelbine; but remained more vulnerable to afatinib. These findings were confirmed with microscopy. Conclusion In summary, we established an NSCLC 3D test system with multiple assays compatible for drug-testing applications of substances with different mechanisms of action. In addition, our data support the usage of microtissues as more accurate tools for drug-efficacy testing with the possibility of long-term cultivation and treatment.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>27424189</pmid><doi>10.1007/s00432-016-2198-0</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0171-5216
ispartof Journal of cancer research and clinical oncology, 2016-09, Vol.142 (9), p.1955-1966
issn 0171-5216
1432-1335
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4978763
source MEDLINE; Springer Nature - Complete Springer Journals
subjects Cancer
Cancer Research
Cell Cycle - drug effects
Cell Proliferation - drug effects
Cisplatin - pharmacology
Drug Screening Assays, Antitumor - methods
Drug therapy
Hematology
Humans
Internal Medicine
Lung - cytology
Lung - pathology
Lung Neoplasms - pathology
Medical screening
Medicine
Medicine & Public Health
Oncology
Original Article – Cancer Research
Original – Cancer Research
Quinazolines - pharmacology
Spheroids, Cellular - cytology
Three dimensional imaging
Tissue Culture Techniques - methods
Tumor Cells, Cultured
Vinblastine - analogs & derivatives
Vinblastine - pharmacology
title Evaluation of assays for drug efficacy in a three-dimensional model of the lung
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T19%3A07%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20assays%20for%20drug%20efficacy%20in%20a%20three-dimensional%20model%20of%20the%20lung&rft.jtitle=Journal%20of%20cancer%20research%20and%20clinical%20oncology&rft.au=Huber,%20Julia%20M.&rft.date=2016-09-01&rft.volume=142&rft.issue=9&rft.spage=1955&rft.epage=1966&rft.pages=1955-1966&rft.issn=0171-5216&rft.eissn=1432-1335&rft_id=info:doi/10.1007/s00432-016-2198-0&rft_dat=%3Cproquest_pubme%3E4144581461%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1810691811&rft_id=info:pmid/27424189&rfr_iscdi=true